|
1
|
Kotb M: Bacterial pyrogenic exotoxins as
superantigens. Clin Microbiol Rev. 8:411–426. 1995.PubMed/NCBI
|
|
2
|
Akbari A, Farahnejad Z, Akhtari J,
Abastabar M, Mobini GR and Mehbod AS: Staphylococcus aureus
enterotoxin B down-regulates the expression of transforming growth
factor-beta (TGF-β) signaling transducers in human glioblastoma.
Jundishapur J Microbiol. 9:e272972016.PubMed/NCBI
|
|
3
|
Akbari A, Mobini GR, Maghsoudi R, Akhtari
J, Faghihloo E and Farahnejad Z: Modulation of transforming growth
factor-β signaling transducers in colon adenocarcinoma cells
induced by staphylococcal enterotoxin B. Mol Med Rep. 13:909–914.
2016.PubMed/NCBI
|
|
4
|
Zhao W, Li Y, Liu W, Ding D, Xu Y, Pan L
and Chen S: Transcytosis, antitumor activity and toxicity of
staphylococcal enterotoxin C2 as an oral administration protein
drug. Toxins (Basel). 8:E1852016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang G, Xu M, Song Y, Su Z, Zhang H and
Zhang C: TNF-α produced by SEC2 mutant (SAM-3)-activated human T
cells induces apoptosis of HepG2 cells. Appl Microbiol Biotechnol.
100:2677–2684. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hosseini Mahmoodzadeh H, Soleimanirad J,
Mehdizadeh Aghdam E, Amin M and Imani Fooladi AA: Texosome-anchored
superantigen triggers apoptosis in original ovarian cancer cells.
Med Oncol. 32:4092015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Terman DS, Serier A, Dauwalder O, Badiou
C, Dutour A, Thomas D, Brun V, Bienvenu J, Etienne J, Vandenesch F,
et al: Staphylococcal entertotoxins of the enterotoxin gene cluster
(egcSEs) induce nitrous oxide- and cytokine dependent tumor cell
apoptosis in a broad panel of human tumor cells. Front Cell Infect
Microbiol. 3:382013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato M, Nakamura Y, Suda T, Ozawa Y, Inui
N, Seo N, Nagata T, Koide Y, Kalinski P, Nakamura H, et al:
Enhanced anti-tumor immunity by superantigen-pulsed dendritic
cells. Cancer Immunol Immunother. 60:1029–1038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong Z, Han C, Hao L, Yang J, Tang W and
Teng G: Preparation and in-vitro bioactivity of a novel
superantigen conjugate targeting bladder carcinoma. J Pharm
Pharmacol. 61:869–875. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dohlsten M, Hedlund G, Akerblom E, Lando
PA and Kalland T: Monoclonal antibody-targeted superantigens: A
different class of anti-tumor agents. Proc Natl Acad Sci USA.
88:9287–9291. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Litton MJ, Dohlsten M, Lando PA, Kalland
T, Ohlsson L, Andersson J and Andersson U: Antibody-targeted
superantigen therapy induces tumor-infiltrating lymphocytes,
excessive cytokine production, and apoptosis in human colon
carcinoma. Eur J Immunol. 26:1–9. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gidlöf C, Dohlsten M, Lando P, Kalland T,
Sundström C and Tötterman TH: A superantigen-antibody fusion
protein for T-cell immunotherapy of human B-lineage malignancies.
Blood. 89:2089–2097. 1997.PubMed/NCBI
|
|
13
|
Ueno A, Arakawa F, Abe H, Matsumoto H,
Kudo T, Asano R, Tsumoto K, Kumagai I and Kuroki M and Kuroki M:
T-cell immunotherapy for human MK-1-expressing tumors using a
fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Anticancer Res. 22:769–776. 2002.PubMed/NCBI
|
|
14
|
Wahlsten JL, Mills CD and Ramakrishnan S:
Antitumor response elicited by a superantigen-transmembrane
sequence fusion protein anchored onto tumor cells. J Immunol.
161:6761–6767. 1998.PubMed/NCBI
|
|
15
|
Si S, Sun Y, Li Z, Ge W, Zhang X, Hu P,
Huang Y, Chen G, Song H, Huang Y, et al: Gene therapy by
membrane-expressed superantigen for alpha-fetoprotein-producing
hepatocellular carcinoma. Gene Ther. 13:1603–1610. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lando PA, Dohlsten M, Hedlund G, Brodin T,
Sansom D and Kalland T: Co-stimulation with B7 and targeted
superantigen is required for MHC class II-independent T-cell
proliferation but not cytotoxicity. Immunology. 80:236–241.
1993.PubMed/NCBI
|
|
17
|
Si SY, Hu PZ, Huang YY, Ye J, Huang Y, Li
ZS, Ge W, Li X, Qu P, Zhang XM, et al: Tumor cells with B7.1 and
transmembrane anchored staphylococcal enterotoxin A generate
effective antitumor immunity. Biochem Biophys Res Commun.
347:208–214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wirth T, Kühnel F and Kubicka S:
Telomerase-dependent gene therapy. Curr Mol Med. 5:243–251. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Autexier C and Greider CW: Telomerase and
cancer: Revisiting the telomere hypothesis. Trends Biochem Sci.
21:387–391. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blackwood EM and Eisenman RN: Max: A
helix-loop-helix zipper protein that forms a sequence-specific
DNA-binding complex with Myc. Science. 251:1211–1217. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumagai T, Tanio Y, Osaki T, Hosoe S,
Tachibana I, Ueno K, Kijima T, Horai T and Kishimoto T: Eradication
of Myc-overexpressing small cell lung cancer cells transfected with
herpes simplex virus thymidine kinase gene containing Myc-Max
response elements. Cancer Res. 56:354–358. 1996.PubMed/NCBI
|
|
22
|
Song JS: Adenovirus-mediated suicide SCLC
gene therapy using the increased activity of the hTERT promoter by
the MMRE and SV40 enhancer. Biosci Biotechnol Biochem. 69:56–62.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Si SY, Song SJ, Xu BX, Zhao G, Tan XQ, Liu
JL, Zhang JZ and Liu ZG: Construction of recombinant adenovirus of
SEA and CD80 genes co-expression regulated by mouse TERT promoter
and identification of its expression in hepatoma cells. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi. 27:717–720. 2011.(In Chinese).
PubMed/NCBI
|
|
24
|
Nielsen SE, Zeuthen J, Lund B, Persson B,
Alenfall J and Hansen HH: Phase I study of single, escalating doses
of a superantigen-antibody fusion protein (PNU-214565) in patients
with advanced colorectal or pancreatic carcinoma. J Immunother.
23:146–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng JD, Babb JS, Langer C, Aamdal S,
Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G,
Alpaugh RK, et al: Individualized patient dosing in phase I
clinical trials: The role of escalation with overdose control in
PNU-214936. J Clin Oncol. 22:602–609. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ihle J, Holzer U, Krull F, Dohlsten M,
Kalland T, Niethammer D and Dannecker GE: Antibody-targeted
superantigens induce lysis of major histocompatibility complex
class II-negative T-cell leukemia lines. Cancer Res. 55:623–628.
1995.PubMed/NCBI
|
|
27
|
Holzer U, Bethge W, Krull F, Ihle J,
Handgretinger R, Reisfeld RA, Dohlsten M, Kalland T, Niethammer D
and Dannecker GE:
Superantigen-staphylococcal-enterotoxin-A-dependent and
antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer
Immunol Immunother. 41:129–136. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma W, Yu H, Wang Q, Jin H, Solheim J and
Labhasetwar V: A novel approach for cancer immunotherapy: Tumor
cells with anchored superantigen SEA generate effective antitumor
immunity. J Clin Immunol. 24:294–301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Green JM, Turka LA, June CH and Thompson
CB: CD28 and staphylococcal enterotoxins synergize to induce
MHC-independent T-cell proliferation. Cell Immunol. 145:11–20.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taub DD and Rogers TJ: Direct activation
of murine T cells by staphylococcal enterotoxins. Cell Immunol.
140:267–281. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu SY, Sui YF, Li ZS, Pan CE, Ye J and
Wang WY: Construction of a regulable gene therapy vector targeting
for hepatocellular carcinoma. World J Gastroenterol. 9:688–691.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pericuesta E, Ramírez MA, Villa-Diaz A,
Relaño-Gines A, Torres JM, Nieto M, Pintado B and Gutiérrez-Adán A:
The proximal promoter region of mTert is sufficient to regulate
telomerase activity in ES cells and transgenic animals. Reprod Biol
Endocrinol. 4:5–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Si SY, Song SJ, Zhang JZ, Liu JL, Liang S,
Feng K, Zhao G and Tan XQ: Cloning of mouse telomerase reverse
transcriptase gene promoter and identification of proximal core
promoter sequences essential for the expression of transgenes in
cancer cells. Oncol Rep. 26:377–382. 2011.PubMed/NCBI
|
|
34
|
Tian XL, Yan Z, Chen J, Zhao WH and Guo W:
Clinical application of highly agglutinative staphylococcin in
cancer treatment updates of the literature. Eur Rev Med Pharmacol
Sci. 20:2718–2725. 2016.PubMed/NCBI
|
|
35
|
Dohlsten M, Sundstedt A, Björklund M,
Hedlund G and Kalland T: Superantigen-induced cytokines suppress
growth of human colon-carcinoma cells. Int J Cancer. 54:482–488.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lando PA, Dohlsten M, Hedlund G, Akerblom
E and Kalland T: T cell killing of human colon carcinomas by
monoclonal-antibody-targeted superantigens. Cancer Immunol
Immunother. 36:223–228. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lando PA, Hedlund G, Dohlsten M and
Kalland T: Bacterial superantigens as anti-tumour agents: Induction
of tumour cytotoxicity in human lymphocytes by staphylococcal
enterotoxin A. Cancer Immunol Immunother. 33:231–237. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dighe AS, Richards E, Old LJ and Schreiber
RD: Enhanced in vivo growth and resistance to rejection of tumor
cells expressing dominant negative IFN-γ receptors. Immunity.
1:447–456. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaplan DH, Shankaran V, Dighe AS, Stockert
E, Aguet M, Old LJ and Schreiber RD: Demonstration of an interferon
gamma-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci USA. 95:7556–7561. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Street SE, Cretney E and Smyth MJ:
Perforin and interferon-gamma activities independently control
tumor initiation, growth, and metastasis. Blood. 97:192–197. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Street SE, Trapani JA, MacGregor D and
Smyth MJ: Suppression of lymphoma and epithelial malignancies
effected by interferon gamma. J Exp Med. 196:129–134. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nishimura T, Nakui M, Sato M, Iwakabe K,
Kitamura H, Sekimoto M, Ohta A, Koda T and Nishimura S: The
critical role of Th1-dominant immunity in tumor immunology. Cancer
Chemother Pharmacol. 46:(Suppl). S52–S61. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rosendahl A, Kristensson K, Hansson J,
Riesbeck K, Kalland T and Dohlsten M: Perforin and IFN-gamma are
involved in the antitumor effects of antibody-targeted
superantigens. J Immunol. 160:5309–5313. 1998.PubMed/NCBI
|
|
45
|
Melief CJ and Kast WM: T-cell
immunotherapy of tumors by adoptive transfer of cytotoxic T
lymphocytes and by vaccination with minimal essential epitopes.
Immunol Rev. 145:167–177. 1995. View Article : Google Scholar : PubMed/NCBI
|
